Literature DB >> 1310362

Seroepidemiology of viral infections among intravenous drug users in northern California.

J B Zeldis1, S Jain, I K Kuramoto, C Richards, K Sazama, S Samuels, P V Holland, N Flynn.   

Abstract

Intravenous drug users are frequently exposed to parenterally transmitted viral infections, and these infections can spread to the general population through sexual activity. We investigated the prevalence of serologic markers for human immunodeficiency virus type 1 (HIV-1), human T-cell lymphotropic virus type I/II (HTLV-I/II), hepatitis B virus (HBV), and hepatitis C virus (HCV) in intravenous drug users and their sexual contacts. Of 585 drug users from northern California tested for these serologic markers, 72% were reactive for the antibody to HCV, 71% for the antibody to hepatitis B core antigen, 12% for HTLV-I/II antibodies, and 1% for the HIV-1 antibody. The prevalence of serologic markers for these four viruses correlated with the duration of intravenous drug use, the ethnic group, and the drug of choice. More than 85% of subjects infected with either HCV or HBV were coinfected with the other virus. All persons reactive to HTLV-I/II antibodies had antibodies for either HBV or HCV. Of 81 sexual contacts tested, 17% had evidence of HBV infection while only 6% were reactive for HTLV-I/II antibodies and 4% for the antibody to HCV. None of this group was infected with HIV-1. We conclude that HTLV-I/II and HCV are inefficiently transmitted to sexual contacts while HBV is spread more readily. Programs designed to discourage the sharing of drug paraphernalia, such as needle and syringe exchanges, should decrease the risk of parenterally spread viral infections in intravenous drug users and thus slow the spread of these infections to the general population.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1310362      PMCID: PMC1003142     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  22 in total

Review 1.  Human immunodeficiency virus infection in children.

Authors:  J Falloon; J Eddy; L Wiener; P A Pizzo
Journal:  J Pediatr       Date:  1989-01       Impact factor: 4.406

2.  High rate of HTLV-II infection in seropositive i.v. drug abusers in New Orleans.

Authors:  H Lee; P Swanson; V S Shorty; J A Zack; J D Rosenblatt; I S Chen
Journal:  Science       Date:  1989-04-28       Impact factor: 47.728

3.  Risk for non-A, non-B (type C) hepatitis through sexual or household contact with chronic carriers.

Authors:  J E Everhart; A M Di Bisceglie; L M Murray; H J Alter; J J Melpolder; G Kuo; J H Hoofnagle
Journal:  Ann Intern Med       Date:  1990-04-01       Impact factor: 25.391

4.  Determinants of needle sharing among intravenous drug users.

Authors:  S Magura; J I Grossman; D S Lipton; Q Siddiqi; J Shapiro; I Marion; K R Amann
Journal:  Am J Public Health       Date:  1989-04       Impact factor: 9.308

5.  The impact of the needle and syringe-exchange programme in Amsterdam on injecting risk behaviour.

Authors:  C Hartgers; E C Buning; G W van Santen; A D Verster; R A Coutinho
Journal:  AIDS       Date:  1989-09       Impact factor: 4.177

6.  Hepatitis C virus antibodies among risk groups in Spain.

Authors:  J I Esteban; R Esteban; L Viladomiu; J C López-Talavera; A González; J M Hernández; M Roget; V Vargas; J Genescà; M Buti
Journal:  Lancet       Date:  1989-08-05       Impact factor: 79.321

7.  Contagiousness of acute hepatitis B. Secondary attack rates in household contacts.

Authors:  R S Koff; M M Slavin; J D Connelly; D R Rosen
Journal:  Gastroenterology       Date:  1977-02       Impact factor: 22.682

8.  Risk factors for human immunodeficiency virus infection in intravenous drug users.

Authors:  E E Schoenbaum; D Hartel; P A Selwyn; R S Klein; K Davenny; M Rogers; C Feiner; G Friedland
Journal:  N Engl J Med       Date:  1989-09-28       Impact factor: 91.245

9.  Patterns of HIV-1 and HTLV-I/II in intravenous drug abusers from the middle atlantic and central regions of the USA.

Authors:  H H Lee; S H Weiss; L S Brown; D Mildvan; V Shorty; L Saravolatz; A Chu; H M Ginzburg; N Markowitz; D C Des Jarlais
Journal:  J Infect Dis       Date:  1990-08       Impact factor: 5.226

Review 10.  Prevalence of HIV infection among intravenous drug users in the United States.

Authors:  R A Hahn; I M Onorato; T S Jones; J Dougherty
Journal:  JAMA       Date:  1989-05-12       Impact factor: 56.272

View more
  33 in total

1.  Lack of awareness of hepatitis C risk among persons who received blood transfusions before 1990.

Authors:  J Buffington; R Rowel; J M Hinman; K Sharp; S Choi
Journal:  Am J Public Health       Date:  2001-01       Impact factor: 9.308

2.  Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif.

Authors:  J Lorvick; A H Kral; K Seal; L Gee; B R Edlin
Journal:  Am J Public Health       Date:  2001-01       Impact factor: 9.308

3.  Effect of age and frequency of injections on immune response to hepatitis B vaccination in drug users.

Authors:  Thanh Q Tran; Carolyn Z Grimes; Dejian Lai; Catherine L Troisi; Lu-Yu Hwang
Journal:  Vaccine       Date:  2011-11-08       Impact factor: 3.641

4.  Hepatitis B virus immunization among young injection drug users in San Francisco, Calif: the UFO Study.

Authors:  Paula J Lum; Kristen C Ochoa; Judith A Hahn; Kimberly Page Shafer; Jennifer L Evans; Andrew R Moss
Journal:  Am J Public Health       Date:  2003-06       Impact factor: 9.308

5.  Survival of hepatitis C virus in syringes: implication for transmission among injection drug users.

Authors:  Elijah Paintsil; Huijie He; Christopher Peters; Brett D Lindenbach; Robert Heimer
Journal:  J Infect Dis       Date:  2010-10-01       Impact factor: 5.226

6.  Characteristics of patients with chronic hepatitis-B virus infection in an urban hospital.

Authors:  David Widjaja; Suresh Yarlagadda; Bheema S Singu; Raghu S Loganathan; Steve Blum; Alan Bloom; Prospere Remy
Journal:  J Natl Med Assoc       Date:  2007-04       Impact factor: 1.798

7.  HCV status knowledge and risk behaviours amongst intravenous drug users.

Authors:  G Vidal-Trécan; J Coste; I Varescon-Pousson; B Christoforov; A Boissonnas
Journal:  Eur J Epidemiol       Date:  2000-05       Impact factor: 8.082

8.  Clinical sequelae of hepatitis C acquired from injection drug use.

Authors:  M J Tong; N S el-Farra
Journal:  West J Med       Date:  1996-05

9.  Adherence to hepatitis B virus vaccination at syringe exchange sites.

Authors:  Frederick L Altice; Robert D Bruce; Mary R Walton; Marta I Buitrago
Journal:  J Urban Health       Date:  2005-03-03       Impact factor: 3.671

10.  Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study.

Authors:  I van Beek; R Dwyer; G J Dore; K Luo; J M Kaldor
Journal:  BMJ       Date:  1998-08-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.